Ionis Pharmaceuticals, Inc.
IONS
$81.84
$0.530.65%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 17.12% | 100.69% | 10.14% | -30.18% | -7.21% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 17.12% | 100.69% | 10.14% | -30.18% | -7.21% |
| Cost of Revenue | -0.34% | -2.04% | -6.85% | -3.97% | 1.52% |
| Gross Profit | 27.17% | 23,662.17% | 29.47% | -135.05% | -18.69% |
| SG&A Expenses | 57.06% | 39.18% | 39.85% | 72.67% | -11.88% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 12.19% | 7.17% | 3.52% | 8.62% | -1.74% |
| Operating Income | -7.75% | 311.55% | 1.77% | -898.61% | -3.76% |
| Income Before Tax | 10.90% | 286.60% | -2.87% | -3,768.41% | -2.34% |
| Income Tax Expenses | 105.88% | -131.25% | 54.67% | -141.41% | -154.85% |
| Earnings from Continuing Operations | 8.45% | 286.45% | -2.90% | -1,026.51% | 4.70% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 8.45% | 286.45% | -2.90% | -1,026.51% | 4.70% |
| EBIT | -7.75% | 311.55% | 1.77% | -898.61% | -3.76% |
| EBITDA | -7.98% | 326.46% | 1.56% | -733.19% | -3.99% |
| EPS Basic | 14.85% | 271.01% | 5.66% | -927.06% | 8.09% |
| Normalized Basic EPS | -1.56% | 307.64% | 8.57% | -642.26% | -0.69% |
| EPS Diluted | 14.85% | 254.19% | 5.66% | -927.06% | 8.09% |
| Normalized Diluted EPS | -1.56% | 281.22% | 8.57% | -642.26% | -0.69% |
| Average Basic Shares Outstanding | 7.52% | 9.03% | 9.07% | 9.72% | 3.68% |
| Average Diluted Shares Outstanding | 7.52% | 24.92% | 9.07% | 9.72% | 3.68% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |